Clinical trials of biosimilars should become more similar
Kay, Jonathan Isaacs, John D.
Kay, Jonathan
Isaacs, John D.
Citations
Altmetric:
Authors
Student Authors
Faculty Advisor
Academic Program
UMass Chan Affiliations
Document Type
Editorial
Publication Date
2017-01-01
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
As many more biosimilars are in development, we recommend that clinical trial design be standardised. This standardisation could be agreed upon and overseen by regulatory agencies around the world. The introduction of consistency across clinical trials should increase confidence in these more affordable biopharmaceuticals, both within the healthcare community and among patients.
Source
Ann Rheum Dis. 2017 Jan;76(1):4-6. doi: 10.1136/annrheumdis-2015-208113. Epub 2016 Aug 25. Link to article on publisher's site
Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1136/annrheumdis-2015-208113
Permanent Link to this Item
PubMed ID
27566795